These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 36291128)

  • 1. Neutral CB1 Receptor Antagonists as Pharmacotherapies for Substance Use Disorders: Rationale, Evidence, and Challenge.
    Soler-Cedeno O; Xi ZX
    Cells; 2022 Oct; 11(20):. PubMed ID: 36291128
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potential of Cannabinoid Receptor Ligands as Treatment for Substance Use Disorders.
    Galaj E; Xi ZX
    CNS Drugs; 2019 Oct; 33(10):1001-1030. PubMed ID: 31549358
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cannabinoid withdrawal in mice: inverse agonist vs neutral antagonist.
    Tai S; Nikas SP; Shukla VG; Vemuri K; Makriyannis A; Järbe TU
    Psychopharmacology (Berl); 2015 Aug; 232(15):2751-61. PubMed ID: 25772338
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cannabinoid CB
    He XH; Jordan CJ; Vemuri K; Bi GH; Zhan J; Gardner EL; Makriyannis A; Wang YL; Xi ZX
    Acta Pharmacol Sin; 2019 Mar; 40(3):365-373. PubMed ID: 29967454
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of rimonabant-like adverse effects of purported CB1R neutral antagonist / CB2R agonist aminoalkylindole derivatives in mice.
    Tai S; Vasiljevik T; Sherwood AM; Eddington S; Wilson CD; Prisinzano TE; Fantegrossi WE
    Drug Alcohol Depend; 2018 Nov; 192():285-293. PubMed ID: 30300803
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic potential of PIMSR, a novel CB1 receptor neutral antagonist, for cocaine use disorder: evidence from preclinical research.
    Galaj E; Hempel B; Moore A; Klein B; Bi GH; Gardner EL; Seltzman HH; Xi ZX
    Transl Psychiatry; 2022 Jul; 12(1):286. PubMed ID: 35851573
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intrinsic effects of AM4113, a putative neutral CB1 receptor selective antagonist, on open-field behaviors in rats.
    Järbe TU; LeMay BJ; Olszewska T; Vemuri VK; Wood JT; Makriyannis A
    Pharmacol Biochem Behav; 2008 Nov; 91(1):84-90. PubMed ID: 18640150
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cannabinoid Antagonist Drug Discrimination in Nonhuman Primates.
    Kangas BD; Zakarian AS; Vemuri K; Alapafuja SO; Jiang S; Nikas SP; Makriyannis A; Bergman J
    J Pharmacol Exp Ther; 2020 Jan; 372(1):119-127. PubMed ID: 31641018
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cannabinoid receptor antagonists: pharmacological opportunities, clinical experience, and translational prognosis.
    Janero DR; Makriyannis A
    Expert Opin Emerg Drugs; 2009 Mar; 14(1):43-65. PubMed ID: 19249987
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cannabinoid-1 receptor (CB1R) blockers as medicines: beyond obesity and cardiometabolic disorders to substance abuse/drug addiction with CB1R neutral antagonists.
    Janero DR
    Expert Opin Emerg Drugs; 2012 Mar; 17(1):17-29. PubMed ID: 22335400
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cannabinoid CB1 receptor antagonists as potential pharmacotherapies for drug abuse disorders.
    Beardsley PM; Thomas BF; McMahon LR
    Int Rev Psychiatry; 2009 Apr; 21(2):134-42. PubMed ID: 19367507
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Blockade of Nicotine and Cannabinoid Reinforcement and Relapse by a Cannabinoid CB1-Receptor Neutral Antagonist AM4113 and Inverse Agonist Rimonabant in Squirrel Monkeys.
    Schindler CW; Redhi GH; Vemuri K; Makriyannis A; Le Foll B; Bergman J; Goldberg SR; Justinova Z
    Neuropsychopharmacology; 2016 Aug; 41(9):2283-93. PubMed ID: 26888056
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overcoming the Psychiatric Side Effects of the Cannabinoid CB1 Receptor Antagonists: Current Approaches for Therapeutics Development.
    Nguyen T; Thomas BF; Zhang Y
    Curr Top Med Chem; 2019; 19(16):1418-1435. PubMed ID: 31284863
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current evidence supporting a role of cannabinoid CB1 receptor (CB1R) antagonists as potential pharmacotherapies for drug abuse disorders.
    Beardsley PM; Thomas BF
    Behav Pharmacol; 2005 Sep; 16(5-6):275-96. PubMed ID: 16148435
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Seventeen years since rimonabant's downfall: reassessing its suicidality risk profile.
    Cohen Y; Kolodziej A; Morningstar M
    Obesity (Silver Spring); 2024 Jul; 32(7):1235-1244. PubMed ID: 38887179
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The CB1 Neutral Antagonist AM4113 Retains the Therapeutic Efficacy of the Inverse Agonist Rimonabant for Nicotine Dependence and Weight Loss with Better Psychiatric Tolerability.
    Gueye AB; Pryslawsky Y; Trigo JM; Poulia N; Delis F; Antoniou K; Loureiro M; Laviolette SR; Vemuri K; Makriyannis A; Le Foll B
    Int J Neuropsychopharmacol; 2016 Dec; 19(12):. PubMed ID: 27493155
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rimonabant improves metabolic parameters partially attributed to restoration of high voltage-activated Ca2+ channels in skeletal muscle in HFD-fed mice.
    Chen B; Hu N
    Braz J Med Biol Res; 2017 May; 50(6):e6141. PubMed ID: 28492810
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A PET study comparing receptor occupancy by five selective cannabinoid 1 receptor antagonists in non-human primates.
    Hjorth S; Karlsson C; Jucaite A; Varnäs K; Wählby Hamrén U; Johnström P; Gulyás B; Donohue SR; Pike VW; Halldin C; Farde L
    Neuropharmacology; 2016 Feb; 101():519-30. PubMed ID: 25791528
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low brain CB1 receptor occupancy by a second generation CB1 receptor antagonist TM38837 in comparison with rimonabant in nonhuman primates: a PET study.
    Takano A; Gulyás B; Varnäs K; Little PB; Noerregaard PK; Jensen NO; Elling CE; Halldin C
    Synapse; 2014 Mar; 68(3):89-97. PubMed ID: 24293119
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacological comparison of traditional and non-traditional cannabinoid receptor 1 blockers in rodent models in vivo.
    Varga B; Kassai F; Szabó G; Kovács P; Fischer J; Gyertyán I
    Pharmacol Biochem Behav; 2017 Aug; 159():24-35. PubMed ID: 28666894
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.